Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.

ABSTRACT:

Importance

List prices set by manufacturers for brand-name prescription drugs in the US have been increasing faster than inflation, although confidential manufacturer rebates offset some of these increases. Most commercially insured patients pay at least some out-of-pocket costs for prescription drugs, and higher patient spending is associated with lower adherence and worse health outcomes.

Objective

To examine whether price changes for brand-name drugs are correlated with changes in patient out-of-pocket spending and whether this association varies by insurance benefit design.

Design, setting, and participants

A cohort study of 79 brand-name drugs with available pricing data from January 2015 to December 2017 was conducted, with data obtained from a national commerci

SUBMITTER: Rome BN 

PROVIDER: S-EPMC8097497 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature